Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Delayed neurotoxicity of intraventricular interleukin-2: a case report.

Literature DB >> 8360712

Delayed neurotoxicity of intraventricular interleukin-2: a case report.

Abstract

A case is reported of a 40 year old woman treated with intraventricular IL-2 for leptomeningeal disease who developed progressive cognitive dysfunction. This deterioration started 3 months post-treatment and worsened over the ensuing 4 years. MRI revealed white matter abnormalities that were not present on the pretreatment scan. Although free of disease, the patient has a subcortical dementia and is unable to work. The potential for progressive brain injury and subsequent disability related to intraventricular IL-2 therapy is discussed.

Entities: Disease Gene Species

Mesh：

Substances：
Interleukin-2

Year: 1993 PMID： 8360712 DOI： 10.1007/bf01050073

Source DB: PubMed Journal: J Neurooncol ISSN： 0167-594X Impact factor: 4.130

7 in total

1. Differential central nervous system responses following single and multiple recombinant interleukin-2 infusions.

Authors: M D Ellison; R J Krieg; J T Povlishock
Journal: J Neuroimmunol Date: 1990-08 Impact factor: 3.478

2. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects.

Authors: J W Mier; G Vachino; M S Klempner; F R Aronson; R Noring; S Smith; E P Brandon; W Laird; M B Atkins
Journal: Blood Date: 1990-11-15 Impact factor: 22.113

3. Transient focal neurologic deficits complicating interleukin-2 therapy.

Authors: J T Bernard; S Ameriso; R A Kempf; P Rosen; M S Mitchell; M Fisher
Journal: Neurology Date: 1990-01 Impact factor: 9.910

4. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial.

Authors: S K Jacobs; D J Wilson; P L Kornblith; E A Grimm
Journal: Cancer Res Date: 1986-04 Impact factor: 12.701

5. Appearance of cytokine-associated central nervous system myelin damage coincides temporally with serum tumor necrosis factor induction after recombinant interleukin-2 infusion in rats.

Authors: M D Ellison; R E Merchant
Journal: J Neuroimmunol Date: 1991-09 Impact factor: 3.478

6. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells.

Authors: K D Denicoff; D R Rubinow; M Z Papa; C Simpson; C A Seipp; M T Lotze; A E Chang; D Rosenstein; S A Rosenberg
Journal: Ann Intern Med Date: 1987-09 Impact factor: 25.391

7. Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier.

Authors: S C Saris; S A Rosenberg; R B Friedman; J T Rubin; D Barba; E H Oldfield
Journal: J Neurosurg Date: 1988-07 Impact factor: 5.115

7 in total

6 in total

1. Intrathecal immunotherapy in CNS tumors disseminating via CSF: preliminary evaluation using different treatment schedules.

Authors: A Salmaggi; A Dufour; A Silvani; E Ciusani; A Nespolo; A Boiardi
Journal: Ital J Neurol Sci Date: 1996-08

Delayed neurotoxicity of intraventricular interleukin-2: a case report.

1. Differential central nervous system responses following single and multiple recombinant interleukin-2 infusions.

2. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects.

3. Transient focal neurologic deficits complicating interleukin-2 therapy.

4. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial.

5. Appearance of cytokine-associated central nervous system myelin damage coincides temporally with serum tumor necrosis factor induction after recombinant interleukin-2 infusion in rats.

6. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells.

7. Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier.

1. Intrathecal immunotherapy in CNS tumors disseminating via CSF: preliminary evaluation using different treatment schedules.

Review 2. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer.

Review 3. New aspects of immunotherapy of leptomeningeal metastasis.

Review 4. Toxicity of treatment for neoplastic meningitis.

Review 5. History and current state of immunotherapy in glioma and brain metastasis.

Review 6. Glioblastoma Treatment Modalities besides Surgery.